Kulukian et al. [73] also determined that tucatinib effectively inhibited HER2 phosphorylation in vitro using the HER2-positive breast cancer cell line BT-474 and observed a minimal inhibition of EGFR phosphorylation in the EGFR-overexpressing skin cancer cell line A431. The gene discussed is ERBB2; the disease is breast carcinoma.